Abhay Singh

TL;DR: This comprehensive review discusses the impact of COVID-19 on health and the immune system of those affected, reviewing the latest treatment approaches and ongoing clinical trials and proposes potential approaches to manage this vulnerable population during this pandemic.

TL;DR: The current understanding and clinical significance of ICUS, CCUS, and CHIP are reviewed to guide physicians in the interpretation of genetic testing results in various clinical settings.

TL;DR: Current management paradigms, current and evolving clinical information, emerging clinical decision-making and sequencing of therapy in advanced, metastatic, or recurrent ALK-positive NSCLC are highlighted.

TL;DR: The current treatment landscape for patients with advanced RCC is discussed, focusing on approved VEGF and checkpoint inhibitors in the first-line setting as well as highlighting landmark combination clinical trials.

TL;DR: It is demonstrated that anthracycline dose intensification with GO may offer higher response rates without increased toxicity in younger patients presenting with de novo AML across European Leukemia Net risk categories.